LifeStance Health Group (NASDAQ:LFST – Get Free Report) and Chemed (NYSE:CHE – Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and target prices for LifeStance Health Group and Chemed, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LifeStance Health Group | 0 | 4 | 5 | 1 | 2.70 |
| Chemed | 0 | 4 | 3 | 0 | 2.43 |
LifeStance Health Group presently has a consensus target price of $14.86, suggesting a potential upside of 7.58%. Chemed has a consensus target price of $603.00, suggesting a potential upside of 9.79%. Given Chemed’s higher probable upside, analysts plainly believe Chemed is more favorable than LifeStance Health Group.
Profitability
This table compares LifeStance Health Group and Chemed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LifeStance Health Group | 4.29% | 4.82% | 3.30% |
| Chemed | 10.61% | 35.18% | 19.43% |
Valuation and Earnings
This table compares LifeStance Health Group and Chemed”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LifeStance Health Group | $1.68 billion | 3.13 | $9.66 million | $0.19 | 72.68 |
| Chemed | $2.66 billion | 2.69 | $265.24 million | $20.90 | 26.28 |
Chemed has higher revenue and earnings than LifeStance Health Group. Chemed is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
85.5% of LifeStance Health Group shares are held by institutional investors. Comparatively, 95.8% of Chemed shares are held by institutional investors. 3.5% of LifeStance Health Group shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
LifeStance Health Group has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.
Summary
Chemed beats LifeStance Health Group on 8 of the 15 factors compared between the two stocks.
About LifeStance Health Group
LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.
About Chemed
Chemed Corporation is a U.S.-based company operating through two principal businesses: VITAS Healthcare, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing, drain-cleaning and water-restoration services. VITAS serves patients with serious illnesses through home-based care and services in hospice facilities and other care settings. Roto-Rooter serves residential and commercial customers with plumbing and drain services, as well as cleanup and restoration following water damage.
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
